Efforts in early detection continue: microalbuminuria screening in diabetes allows earlier ACE inhibitor use, and emerging biomarkers in hypertension may soon identify subclinical kidney damage for timely intervention [139]. This evidence concerns the gene ACE and hypertensive disorder.